atepeq/tico19 huggingface dataset:
To pilot implementation of a scheme for collection of convalescent sera with antibody profiles among recovered cases of COVID-19 discharged to the community
Dawari cida diobe "convalescent sera" mowobe dawu am COVID-19 ye sǝta ngazana ye lan suro ngurobe ro salamtǝna.
We intend to capture the following.
Awowa anyi tawo nyiyanyiye.
Clinical workload related to reports of COVID-19 using the codes created to flag cases, those being assessed and where the infection is located are excluded (Figures 2-​-44)
Kǝrau cidawa litaribe rifotta COVID-19be'a leyatasuwa ashirbe do kessa dǝ nankaro tǝnandǝna dǝ faidatinna ro, sandi kulastǝ tǝdinma-a kuru na kwasa dǝ daana-a dǝ dawun ba,
Foreign countries visited in the last 28 days
Lardǝwa diyabe suro kau 28 kozǝnayen ziyaratǝna ma.
Existing codes that may have utility (Tables 1-​-3).3).
Suwa ashirbe so do waniye faidatin ma (Tewur 1 -- 3).3).
Many GPs and primary care teams may not realize that important relevant data can be coded.
GPs wa-a jamiwa nǝlewa ro cistaabe badiyarambe kada'a sapsawi bayanbe faida'a mowonzǝ su ashirbe tǝkkin ro waniye nozanyi ro waljin.
There is also the potential during any pandemic to monitor the effectiveness of any transmission control measures.
Kuru mowontǝ mbeji suro wawa jili wi yen yaye faidatǝ katapwa faltǝ au tartǝgǝ daptǝye gotǝna dǝ ninitaabe.
Reliable coding of letters and test results that will show an infection has become either confirmed or excluded
Su ashirbe watiya-a tamoramwa tesbe so ro ikkoye fǝlejin kwasa dǝ tawattǝgǝna au ba ro tǝdǝna.
The methods will follow the approach used in the current influenza surveillance system and recent serology study, and includes five components: (1) primary care clinical surveillance; (2) virological surveillance; (3) population serological surveillance; (4) convalescent sera in cases; and (5) data curation.
Duluwuwa dǝ nzundu infuluyenza ro shim ikkoye kǝmaaye dǝ-a kǝra kǝla 'serology' yen karungu ro tǝdǝna dǝ-a zǝgayin, kuru suronzǝn awowa uwu dǝga: (1) shim ikko cistǝgǝ badiyarambe liyitabe; (2) kuli kwasabe ro shim ikko; (3) "serology" jumla amma ye ro shim ikko; (4) sera ngatǝ sǝdin ma suro kessa yen; kuru (5) sapsawi bayanbe na fallo saptǝgǝ.
The NHS uses the Systematized Nomenclature of Medicine Clinical Terms (SNOMED CT) system of coding, which is normally only updated twice annually.
NHSdǝ nzundu su ashirbe ikko shiro"Systematized Nomenclature of Medicine Clinical Terms (SNOMED CT) gulzayin dǝ faidatin, shi doni saa wo son indi njong ro bǝlintǝyin ma.
There was added complexity as some computerized medical record (CMR) suppliers use the Read coding systems (Read clinical terms version 3 – CTv3), which is no longer updated.
Nǝm zau tǝrana mbeji saunzǝ dǝ am rekod litaribe kompiutabe gǝmzayindǝ awo shiro "Read coding system" sayin dǝ faidatayin dǝ ro (Read clinical terms version 3 – CTv3), shi doni tǝmma ro bǝlintǝyimba ma.
Additionally, there were no clinical codes to record COVID-19 in early February 2020.
Adǝ ro nzǝra lan, su ashirbe litaribe COVID-19 rekod dio be ba badiyaram kǝntagǝ February be saa 2020be lan.
Therefore, the two main GP system suppliers added the five terms shown in Table 4 as system-wide local codes.
Adǝye sǝkkǝ, am nzundu GP gǝmzayin kura kura indi dǝye awowa uwu Tewur 4 lan fǝletǝna dǝ cashara naptǝ suwa ashirbe fatobe nzundu dǝ sapcinbeyen.
A UK emergency release of SNOMED CT concepts for COVID-19 was also subsequently made available across all CMR systems (Table 4).
Tulo duwasashibe UKye "SNOMED CT concepts"be COVID-19 ye dǝye mbeji ro tǝdǝna nzunduwa CMRbe samma son (Tewur 4).
The intention is that these will eventually be mapped to the new SNOMED CT concepts as they become available, allowing recording of relevant data (Multimedia Appendix 1).
Awo nyiyatǝna dǝ shima sandi anyi samma so waiyya suro ''SNOMED CT concept'' bǝlinbe dǝ ro tǝkkin sa mbeji ro walzaiyya, adǝye kolzǝ sapsawi bayanbe faidajin samma rekod ro tǝkkin (Multimedia Appendix 1).
The key requirements for this release were the ability to code (Table 4) a case of COVID-19, exposure to risk of infection (travel to an area where there may be a higher risk), contact with anyone infected with COVID-19, a report that a person had been tested for COVID-19, and that the disease had been excluded (likely a negative test).
Tulo adǝ nankaro awo mǝradǝtǝna kura dǝ shia nǝm mbeji su ashirbe (Tewur 4) kes COVID-19be ro ikko, fujiwo kwasa gotabe ro gawo (na fujiwo ngǝwu'a ro bǝlagrotǝ), kam laa COVID-19ye sǝtana'a leta, rifot kam laa COVID-19 tiyinzǝn mbeji tesye fǝlezǝnabe so, kuru kwasa dǝ tutuluwuna (misallo tes tiyi lan ba fǝlejin ma).
In addition, practices are now able to code any foreign travel undertaken, including the ability to record visits to multiple countries (implemented February 8, 2020).
Adǝ ro nzǝra lan, cidawa tǝdinye kǝmaa dǝ raksa bǝlaguro lardǝ diyabe ro tǝdǝna jili wi yaye ro su ashirbe sakkin, raktǝ do ziyara lardǝwa kadaro taadǝna be rikod ro ikkon kunten (Kǝntagǝ February e 8, 2020 kokkatǝ).
Figures 2-​-44 show the EMIS web implementation.
Figures 2--44 dǝ "EMIS web implementation" fǝlejin.
Currently, virology samples for influenza surveillance are accompanied by a standard request form.
Kǝrmaa ro, samfǝrra 'virology'be infuluyenza ro shim ikkoye dǝ fom matabe gǝdima sha zǝgayin.
For COVID-19, we will create a new request form that will record:
COVID-19 ro, andeye fom matabe bǝlin tannden shi doni rekod ro sǝkkin:
Date of onset of symptoms
Kau kǝntagǝbe alamawa badizǝna be
Diagnosis of any of the following:
Awowa anyi litarin mbeji gultǝna wa:
Acute bronchitis/bronchiolitis in those younger than five years
Kwasa buronkayetis/buronkiyolayetisbe nduli saa uwun cidiyan ro
Lower respiratory tract infection (LRTI)
Kwasa zawal yintǝbe cidiyabe (LRTI)
History of fever (Y/N); measured (Y/N); if yes, level
Tarihi kangebe (A'aa/A'aa); ngaltǝna wa (Aa'a/A'aa); Aa'a maa, ndawu
Shortness of breath (Y/N), if measured: oxygen saturation and respiratory rate
Yintǝ gana (Aa'a/A'aa), ngaltǝna maa: tuskatǝ oksijinbe-a nǝm ngǝwu yintǝbe-a
Recent travel (Y/N); if yes, countries visited in last 14 days
Karugu ro bǝlaguro (Aa'a/A'aa); Aa'a maa, lardǝwa suro kau 14 kozǝnayen ziyaratǝna
Contact with a named person with confirmed COVID-19 (Y/N) with a free text comment about the level of certainty
Kam laa su-a COVID-19'a ro tawattǝgǝna ro letǝgǝ (Aa'a/A'aa) bayan kǝla daraja tawadǝbe'a ro.
These codes will be grouped ontologically into “definite”, “probable”, “possible”, and “not a case” using our standard approach to grouping codes (Table 5), which has been used previously across disease areas.
Suwa ashirbe anyi jam'u ro tǝkkin "tawadǝ", "waniye", "mowonjin", kuru "kes gǝnyi" nzundunde gǝdima su ahirbe jam'u ro ikkobe faidatiyenna ro (Tewur 5), shi doni buron na'a kwasa'a lan faidatǝa ma.
The RCGP RSC definition for ILI is shown in Multimedia Appendix 2.
RCGP RSC ye ma'ananzǝ ILI be dǝ suro Multimedia Appendix 2be lan fǝletǝna.
Public Presentation of Data Using an Observatory and Dashboards
Sapsawi bayanbe jama meu ro na wutin "observatory-a dashboard-a" lan yita gattǝgǝ
We will develop an observatory to present data nationally and a dashboard for feedback to practices about their data quality and collection of virology and serology samples.
Andeye na wutabe sapsawi bayabe lardv samma so ro yita gattǝgǝbe tanden kuru 'dashboard' jawawu kǝla nǝm ngǝla sapsawi bayanbe-a kuru samfǝrra 'virology'be-a 'serology'be-a mowobe kǝlan.
This is based on coding described in Table 4.
Adǝ su ashirbei kko suro Tewur 4 ye lan tukkuwaltǝgǝna dǝro wungatǝgǝ.
Definite case will be presented on our dashboard as “cases” of COVID-19.
Kes tawadǝ-a 'dashboard' nde lan fǝlein "kessa" COVID-19be ro.
Possible cases will be presented as “Under investigation” (investigating).
Kessa mowonjin dǝ naptǝ "Cidiya kulashi yen" ro fǝletin (kulastin)
“Not a case” will be presented as “Excluded”.
"Kes gǝnyi" dǝ "tutuluwuna" ro fǝletin.
Online data has been established within the initial few weeks in the COVID-19 Observatory (Figure 5), indicating the overall number of patients and rate per 10,000 patients of cases confirmed or under investigation, as well as where the virus is excluded.
Sapsawi bayanbe 'Online' tutuluwuna suro magǝwa gana badiyarambeye lan na COVID-19 kurube lan (Figure 5), adadu am dondiye samma-a kuru nǝm ngǝwu kessa awatǝna ye suro kes 10,000 au cidiya kulashiyen, kuru na kuli kwasabe dǝ ba ro tawattǝgǝna'a.
We have the option to move to twice weekly surveillance reports with a scope to change this to daily reporting.
Karnonde magǝ lan indi ro rifot shim ikkobe ro kotǝbe mbeji, hangal nde wajiya wo son rifot dio ro iyyenna ro.
We will continue virology sampling from our sentinel practices, rather than discontinuing as seasonal influenza declines.
Samfǝr dio "virology"be dǝ gonye koyen, susu wanǝm koltǝbe ro zaman inuluyenzabe kojiya.
Additionally, we will recruit more surveillance practices.
Adǝ ro nzǝra lan, cidawa shim ikkobe gade soye gonyen.
The RCGP RSC virology practices will aim to undertake 200-300 nasopharyngeal swabs per week across the RCGP RSC sentinel network, collecting specimens across all age bands.
RCGP RSCye cidawanzǝ "virology"be dǝ magǝ wo son" nasopharyngeal swabs" 200-300 sǝdiya sǝraa ewok RCGP RSC samma son, "specimen"wa na kura ba gana bayen tumoyin.
In addition to the inclusion criteria for influenza virology surveillance (ILI, acute bronchitis/bronchiolitis), participating practices will take nasopharyngeal swab samples from any people showing acute symptoms of LRTI if the onset of symptoms is within 7 days.
Awowa do shim ikko 'virology' infuluyenzabe ro kwasa'a (ILI, buronkayetis/buronkiyolayetis zauro zau) sǝkkin ro kǝltǝgǝ lan, cidawa do tǝdinye dau ro tǝkkin samfǝr "nasopharyngeal swab"ye na ndu yaye alamawa LRTIbe fǝlejin yen badiyaram alamawabe dǝ kau 7 kozǝnyi maa.
RCGP RSC research officers and practice liaison staff will manage practices to achieve a total national sample of 200-300 swabs per week.
RCGP RSC ye cidawunzǝ kulashi diobe-a cidawu "practice liaison staff" sayin dǝ'a ye cidawa ro cissayin lardǝ samma son kǝnasar samfǝr 200-300 magǝ wo son gotabe fando ro.
This could be increased if PHE modelers require more samples.
Adǝye mowonzǝ tǝrayin cidawu PHEbe samfǝr ngǝwu mazaiyya.
Samples from each practice would be spread across the following age groups: &lt; 5 years, 5-17 years, 18-64 years, and 65 years and older
Samfǝrwa cida wo soye dǝ jam'uwa ngǝlibe anyi ro tartǝyin: saa < 5, saa 5-17, saa 18-64, kuru saa 65-a adǝ ro kura wo-a.
Samples (swabs or serum) collected will be sent via prepaid envelopes addressed to the appropriate PHE laboratory for analysis.
Samfǝrra (swab au serum) tǝmona dǝ lab PHEbe sandǝna ro embulop men zutǝyin.
All samples collected will be tested for the presence of influenza and COVID-19.
Samfǝrra tǝmona samma so infuluyenza-a COVID-19-a ro jarabtin au tes tǝdin.
Additionally, PHE will retrospectively test any influenza virology samples collected between early and mid-February 2020 for COVID-19.
Adǝ ro nzǝra lan, PHEye samfǝrra 'virology' infuluyenzabe jili wi yaye ndi kate badiyaram februaryyen sǝta dawunzǝ ro kude saa 2020yen tǝmona ro tes COVID-19ye sǝdin.
Practices will still follow the PHE protocol for COVID-19 with respect to people at risk of infection who should be signposted down the containment pathway, rather than physically attend their practice.
Cidawa dǝ ka'idawa PHEbe COVID-19be dǝ zǝgayin nasha am suro fujiwo sandiya kwasaye kǝntabe lan kasharu sandi do sandiya zawal kwasa dǝ daptǝgǝye ro tǝkkǝna ma ngǝla wo ma, ngai cidawanza dioye susu dǝ ro.
Direct testing of those who attend surgery remains permitted, but we have also rolled out self-swabbing at home.
Tes dio am tiyata ro rǝbtaana ye dǝ kasatkata ro kara, amma swab kǝlaro dio tuluyena.
Summary of processes are detailed in Multimedia Appendix 3.
Kasartǝ duluwuwa ye dǝ Multimedia Appendix 3 lan bayantǝna.
Everyone with an ILI or a respiratory illness who contacts a GP (eg, phones for an appointment) should be asked specifically about recent travel to China and other countries flagged in current PHE advice, or if they have had contact with other people with COVID-19.
Ndu yaye kam nǝm dondi infuluyenza-a samun shi lan mbeji au nǝm dondi yintǝbe shi lan mbeji kuru GP ro letǝgǝna (misallo waya loktu gǝnatǝ nankaro) sandiya tuworǝ taganas ro kǝla bǝlaguro China-a lardǝwa gade so-a yen, au am COVID-19-a ro letaana la letaanyi ro.
If these screening enquiries are positive, the patient would be advised to not come to the practice but instead to follow the PHE flow sheet.
Awowa sǝkǝrinin lan kulastǝna dǝ tawadǝ au mbeji ro wallono maa, kam dondi dǝ ro shawari tin wande isǝnyi ro kuru susu dǝ ro "PHE flow sheet" dǝ zǝ'a.
This can be by a reception or clinician staff, depending on individual practice protocol.
Adǝye cidama litaribe men yaye mowonjin, ka'idawa cidabe ngǝmye lan Kara.
These calls should be coded into the GP CMR system and can be reported as part of the RCGP RSC weekly return.
Bowotǝwa anyi suro nzundu GP CMR suwa ashirbe ro tǝkkin kuru mowonzǝ rifotnzǝ tǝdin naptǝ RCGP RSCbe magǝ wo son kalaktǝyin ma.
We have developed training material to support this coding (Multimedia Appendix 4).
Karewa allamtǝye tandena lamar su ashirbe ikkoye dǝ banata ro (Multimedia Appendix 4).
These include prompt cards for:
Adǝye su ron mbeji kati wa:
Practice reception or triage staff: for coding of any patients calling the practice with symptoms of acute respiratory infection with a history of travel to important areas based on PHE advice
Cida mowo au cidawu triagebe: su ashirbe ikko kam dondi cida dǝ'a nǝm dondi nasha yintǝbe nankaro bowojin shi doni tarihi bǝlaguro na'a PHE ye faida'a gulzǝna ro sǝdǝna.
Administrative staff or clinicians who code: to encourage consistent coding of results for any suspected cases, including coding of negative results for exclusion
Cidawu cidaram notobe-a cidawu litaribe -a do su ashirbe sakkin: tamoramwa kes tǝmatǝna jili wi yaye ro su ashirbe ikko, tamoramwa kwasa ba guljinye ro su ashirbe ikko kunten.
Practices participating in virology surveillance will opportunistically collect blood samples from patients coming into the practice for a routine blood test.
Cidawa do shim ikko 'virology ' yen sandi mbeji dǝ daata ro samfǝr bu'ye na am dondi tes bu'ye ngai dio ro isana yen gozayin.
Patients who attend their practice for a routine blood test will be asked to provide an additional sample for serology.
Am dondi do jarawa bu'ye ngai ro isana dǝ sandiya tuworǝ bu gade jarawa "serology" ye nanzan gotin.
We have conducted initial searches within the RCGP RSC database to look at the number of full blood count (FBC) results and overall rates in adults and children (Figures 6-​-9).9).
Andeye kulashi buroye diyena suro na RCGP RSC sapsawi bayanbe sapcin dǝn, adadu tamoramwa "full blood count (FBC)"ye kuru nankaro kuru nǝm ngǝwu dawu ammurawa-a nduli-ayen (Figures 6--9).9).
An FBC is one of the most common tests performed, and we hope this will give an approximate indication of overall numbers of blood tests performed.
FBC dǝ shi tes zauro ngǝwu ro tǝdin soye falnza, kuru tǝmanyena adǝye tessa buye tǝdin samma soye adadu cin ro.
The sampling rate, per 100,000 patients was highest for children 15-17 years of age and 60 year or older in adults, with the lowest rates in children 0-4 years of age and 18-29 years of age in adults (Figures 6-​-99).
Adadu am ngaltǝna ye dǝ, suro am dondi 100,000 ye dǝ duli ma zauro nguwu wo ngǝli 15-17 kuru ngǝli 60 aw samin rashidiwa lan, adadu zauro gana duli lan ngǝli 0-4 kuru ngǝli 18-29 suro rashidiwa yen (Figures 6--99).
We will provide 1000 serology baseline samples across all ages that reflect the varying rates of attendance by age.
Bu rizabtǝ 1000 kǝla ngǝli samma so yen yiyen shi dǝwo adadu ngǝliye wo fǝlejin ma.
Additionally, we will test if we can obtain these all from virology practices to enhance the yield.
Adǝyeyi ma, ande ye rizabnye ruyen awowa adǝ samma so ilmu kǝla kwasa kulastaye dǝn fandiyen wa ro kuru fando dǝga ngalautǝ ro.
A good geographical spread is important, so PHE can advise on areas where serology will most usefully be collected.
Na kura kornǝm gotǝ dǝ zauro faida, adǝ nankaro PHE ye raksǝ shawari cin kǝla ndara bu ngalte dǝ tǝdiya sandǝna wo yen
This will be followed by 800 samples monthly.
Ngawo adǝyen kǝntawu wo son bu gotǝ 800 ngawo dǝ zǝayin.
The sample will be stratified with 200 specimens for prepandemic survey (100 for monthly) in the following age groups: &lt; 5 years, 5-17 years, 18-64 years, and 65 years or older.
Bu gotǝna dǝ sha kashi 200 yaktin kulashi kawu kwasa dǝ ye ro (100 kǝntawu wo so ye) futu kashi nglibe adǝ yeyi ro: < 5 saa, 5-17 saa, 18-64 saa, kuru saa 65 aw samin.
The younger patients, in many practices younger than 14 years, and in nearly all for children younger than 8 years will require pediatric serology surveillance.
Duliwa dondi sǝnana so dǝ, awo nguwu so ro tǝdin dǝ saa 14 ro ganawo dǝn, kuru samma so karǝngeya duli saa 8 ro gana wo dǝn kulashi bu gotǝye duli sǝnanaram ye mǝradǝzain.
We will develop a new request form for practices to capture recent travel and exposure to COVID-19.
Ande ye fom bǝlin korobe tanden kǝndo ro bǝlaro karǝngǝ ye-a COVID-19 ro letǝgǝ-a fǝlejin ma.
We will pilot a scheme for collecting convalescent serology from people with confirmed cases and who have had an acute virology sample at the time of their infection.
Ande ye fasal la bu am kwasa dǝn ngazana ye ngaltǝ badinyiyen kǝla am kwasa dǝ tawatkata yen-a kuru am dǝwo zauro bunzan kuli kwasabe mbeji ro fǝlezǝna so dǝn sa sandiya zamtǝna dǝn.
This is to identify a carrier state in patients who have recovered from the virus but may continue shedding the virus.
Adǝ ye hal kam kuli kwasabe dǝn ngazǝna dǝwo waneye kwamison kuli kwasabe dǝ tarzayin ye dǝ notǝ ro.
If there are a small number of cases, this may assist in developing a test kit for patients to take to their own GP and explore its acceptability to patients.
Adadu kwasa dǝ ye dǝ gana ma, adǝ banazǝ awo ngaltǝye dǝ amnza dondi dǝ ro satandin goza GP nza ro sadin kuru futu am dondi dǝ ye suwondai dǝ asuzain.
If there are a large number of COVID-19 cases nationally, convalescent samples could be collected from RCGP RSC practices where there are confirmed cases, with the ability to link to the full medical record.
Adadu am COVID-19 ye zamzǝna dǝ lardǝ dǝ samman nguwu ro waljiya, bu am ngazana ye dǝ gotin RCGP RSC kǝndo lan na dǝwo kwasa dǝ mbeji ro tawatkata dǝn, raktǝ kakkadǝ litaribe ro kamil ro kǝltǝyin men.
This process may include checking pseudonymized NHS numbers for positive individuals at RCGP RSC practices, checking current PHE guidance regarding considerations of infectiousness for confirmed cases, and offering the patient an appointment following the previously mentioned process.
Zawal adǝ ye suro dǝn kulashi lamba NHS ye gǝrata ye am tiyinzan mbeji ma ye na RCGP RSC kǝndo yen mbeji, Kulashi kashimo PHE ye kǝrmaye kǝla nǝm tartra kwasa tawatkata ye, kuru kam dondi dǝga dotǝ-a ngawo zawal manatǝna dǝ yen.
This needs to be carefully coordinated nationally across the network and may require PHE to ensure individuals are not contacted by multiple agencies.
Adǝ ye mǝradǝ karaskata ro kǝlakǝl yoye lardǝ samma so ye mbeji kate kate gawilwu samma so yen kuru PHE ye mǝradǝ am so dǝ cidawu kada ye sandiro manazanyi ro tawattǝ ye mbeji.
RCGP RSC could provide a useful structure to channel the initial contact once PHE has made a request.
RCGP RSC ye fasal la faida suwudin kam buron matǝgǝna dǝga zutuye tinyi sa PHE ye majiya.
The RCGP RSC practices participating in the annual influenza virology surveillance have started sampling from patients showing symptoms of a LRTI.
RCGP RSC kǝndo dǝ suro nazaru saa saa ye kǝla tantayi yen sadin mbeji ma dǝ bu am dǝwo alamawa LRTI ye fǝlezǝna ye gotǝ badizana.
All samples received are being tested for influenza and COVID-19.
Bu dǝwo tǝmona dǝ samma kange tantayi-a COVID-19-a mbeji la ba ro kulaskatǝ.
The RCGP RSC will explore ways to collect convalescent samples from any patients tested positive for COVID-19 through the extension of the virological surveillance.
RCGP RSC dǝ ye zawalwa bu am kwasa COVID-19 yin ngazǝna ye gotǝye wujin zawal kulashi kela kuli kwasabe dǝ farakǝgǝ men.
From the start, we will be carefully curating data to ensure that it can be used for future studies.
Badiyaram dǝn, ande ye bayanna samnyen nazaru fuye dǝn faidatin ro tawattǝgǝ ro.
Our clinical data will be linked to virology.
Bayannande litariye dǝ kulashi kwasabe dǝ ro kǝltǝyin.
We will curate our data using the Findable, Accessible, Interoperable, Reusable principles.
Bayanna samnyen kaidawa ndetuwondin ma, Fando butuwa ma, Nduso ye raksǝ faidatin ma, Waltǝm rangnǝm faidatǝmin ma dǝn faidatǝyen.
To facilitate this our data set is listed with Health Data Research UK and the European Health Data Evidence Network.
Bayannande adǝga banatǝ ro bayanna kulashi nǝlefayey UK-a kuru European Health Data Evidence Network-a yen isabtǝna.
The statistical methodology is in support of a policy approach to widespread disease outbreak, where so-called nonpharmaceutical interventions (NPIs) are used to respond to an emerging pandemic to produce disease suppression.
nzundu isau men sursur kǝngaye dǝ kaida kwasa nguwu ro tartǝgǝyin dǝga kaltǝge ye dǝga jirezǝgǝna, na dǝwo awo bana kurunye gǝnyi (NPIs) ma lan faidatǝ kwasa tartǝgǝyin ma dǝ kaltǝgǝ ro awo kwasa ratsǝyin ma tǝnandǝna.
This policy aims to reduce contact rates in the population and thereby reduce transmission of the virus.
Kaida adǝ awo nganzazǝna dǝ shima suro jama ye dǝn adadu kam ro letǝgǝye dǝ fulutu ro adǝye sǝkǝ kuli kwasabe dǝ tartǝgǝ dǝ fulutin.
To implement this the UK government has recently articulated the desire to implement population self-isolation measures.
Awo adǝga tawattǝgǝ ro gomnati UK ye dǝ ye nyanzǝ kataabwa jamaye kǝlanzala men kǝlanza kortǝye dǝ bayanzǝna.
By targeting the reproduction number (R) (the average number of secondary cases each case generates) and aiming to reduce the R to below 1, the policy seeks to reduce case numbers to low levels or (as seen in previous outbreaks with severe acute respiratory syndrome and Ebola) to eliminate human-to-human transmission.
Adadu yamboye au fafanǝm nguwutǝye (R) dǝ nganzatǝ men (adadu dǝwo dawu dawu ye ma kwasa kǝn ndimi ye dǝwo kwasa bi so sambin ma dǝ) kuru nyanzǝ R dǝga fulunǝm 1 yin cidaan ro kudoye, kaida dǝ kasadǝnzǝ adadu kwasabe dǝ cidâ ro saam ganatǝgl ye mbeji aw (futu ngawon kǝla falangtǝ kwasa yintǝye -a Ebola-a yi turuna dǝyeyi) kate kate adamngana yen tartǝgǝ dǝ ba ro diwo ro.
As the experience from the 2009 H1N1 pandemic has shown, NPIs can be a crucial component of pandemic mitigation.
Futu kwasa dinaye H1N1 2009 ye dǝ ye fǝlezǝna dǝ yeyi, NPIs dǝ raksǝ awo dǝwo faida fal kwasa dinabe adǝga kǝriwtǝye ro waljin.
Key to the focus of our study will be the estimation of peak cases in the population and continual monitoring by data collection and modelling the potential growth and emergence of subsequent peaks in new cases as social distancing measures are relaxed.
Nazaru nde dǝ ye na hangal cin dǝ shima adadu kwasa dǝ ye zauro nguwu ro zuwana ma suro jamaye dǝ tǝadirtǝgǝ kuru datǝ ba ro Sursuri kǝnga-a bayanwa sabtǝ men kuru futu tǝraiya waljin ro kuru so kuru ngawo dǝn adadu zauro nguwu ro kǝmba bǝlin ro kwasa dǝ waatǝ so sa katabwa am so ro fattǝgǝ ba ye dǝ kabaitǝgǝya.
There has already been publication of important disease epidemiological measures concerning the outbreak of COVID-19 in mainland China.
Kerma ro ruwo lǝbtǝna mbeji kǝla nazaru kwasa kura ye katabwanzǝ gotin so yen kǝla falangtǝ COVID-19 ye suro lardǝ China yen.
A further fundamental measure in pandemic dynamics is the length of time from infection to when a person is infectious to others and the mean duration of infectiousness.
Katab gade zauro faida suro kwasa dina ye dǝ ye fafaltǝnzǝ dǝ shima loktu dǝwo gojin ma dǝ sa zamtǝye dǝn tai sa kam dǝ ye am gade ro tarzǝyin ro waljin ro kude.
These factors, if estimated accurately, will give good predictions for the likely length of the pandemic, the final number of infected cases.
Awowa adǝ, kalkal ro isabtǝna ro waljiya, loktu kwasa dǝ ye gojin ro tǝmata kalkal ro cin, adadu datelaye am kwasa dǝ ye zamzǝna ye-a.
We intend to apply approximate Bayesian inference (ABC) to (possibly spatially heterogeneous) Susceptible-Exposed- Infectious-Removed (SEIR) stochastic epidemic models.
Ande ye nyaye approximate Bayesian inference (ABC) to (possibly spatially heterogeneous) Susceptible-Exposed- Infectious-Removed (SEIR) stochastic epidemic models so dǝn faidatǝ ro.
Such techniques are highly parallelizable and have been successfully applied to many fields including disease transmission modelling.
Nzunduwa jili adǝ zaumaro raktǝ kǝlatilowa ro rataltǝyin kuru man fellawa gade son faidatǝ kǝnasar turuna surodǝn nzudu dǝwo kwasa tartǝgǝ ngaltǝye ye mbeji.
They are particularly suited to situations where likelihood functions are absent and where more traditional approaches such as Markov chain Monte Carlo are impractical.
Sandi adǝ musamman ma ro halla sa awo fuwun wajin so dǝ raktǝ tǝmatinmba ro waljiya kuru loktu zawalwa kureye ada alama Markov chain Monte Carlo so dǝ muwonzǝ faidatinmba ro waljiya.
Such an approach has been demonstrated to work effectively on the ASPREN surveillance data, a network of sentinel GPs and nurse practitioners who report deidentified information on ILIs and other conditions, where issues such as missing data and the need to model the observation process itself has been successfully addressed.
Katab adǝ fǝlezǝna ngǝlaro cidajin ro kǝla ASPREN surveillance data, fasal la sentinel GPs ye kuru cidawu liyitariye dǝwo hawar kǝlanzǝ asutunyi ma kǝla ILIs-a halla gade-a yen sadin ma do-a, na dǝwo lamarwa bayanna fatsǝna ye-a mǝradǝ nzundu sursuri kǝngaye dǝga Waltǝm sasǝrtǝye dǝga ngǝla ro manatǝna dǝn.
Furthermore, peaks in new cases have been estimated by distributional methods.
Adǝyeyi ma, kwasawa bǝlin ye adadunzǝ zauro nguwu ma tǝadir nzǝ dǝ nzundu shiro distributional gultin dǝ men isabtin.
Estimates of the parameters of the SEIR model are tractable on large data sets because of parallelizability, and these methods have been implemented in several R libraries; we intend to use the libraries ABSEIR (deposited on GitHub: https://tinyurl.com/vqu35cj) and abctools (https://tinyurl.com/tfjavz4) to estimate epidemic measures on a weekly basis.
Tǝadir nangam SEIR model ye dǝ faidatǝ butuwa kǝla bayanna nguwu yen sawo raktǝ samǝntǝyin nankaro, are tractable on large data sets because of parallelizability, kuru nzunduwa adǝ kǝla ku njim kǝraye R ye kadan faidatǝna; njimwa kǝraye adǝn faidatǝ ro nyanyena ABSEIR (deposited on GitHub: https://tinyurl.com/vqu35cj) and abctools (https://tinyurl.com/tfjavz4) katabwa kwasa dinaye mawu mawu lan tǝadir tǝro.
Since we are fitting an SIR-epidemic model in the ABC routine, we anticipate that our results will be robust against weekly case data containing relatively small counts.
Fasal SIR-epidemic model ye kǝltabe suro letǝgǝram ABC ye ro yikiyen dǝga. Tǝmanyena natijande dǝ zauro ngǝla ro waljin kǝla bayanna mawu mawu ye kǝla kwasa ye dǝn shi dǝwo ne suronzǝn adadu gana ma ye dǝn.
For example, see for the ABC methodology applied to the Tristan da Cunha common cold data from 1967, where counts of I (number of infectious cases) and R (number of recovered cases) are in the tens at most.
Misallo, wune nzudu BBC ye dǝ kǝla applied to the Tristan da Cunha yen kǝla bayanna tantayi yen sa 1967 faidatǝna, ma dǝwo isawu where counts of I ye dǝ (adadu kwasawa tartǝgǝyin ye) kuru R (adadu am ngazana ye) so dǝ nguwu so ro Kate kate meu yen.
Finally, in addition to the above methodology we will employ the Kaplan-Meier method with two outcomes (death and recovery) to estimate the case fatality ratio.
Dare dajilamen, nzundu samiye dǝn nguron ro nzundu, nzundu Kaplan-Meier dǝn faidatǝyen natija indiya (kǝrmu-a ngatǝ-) kǝrmu kwasa dǝ ye dǝ tǝadirtǝgǝ ro.
This approach is independent of the ABC methodology and will allow comparisons between estimates from the two modelling approaches to judge robustness of results.
Zawal adǝ nzundu ABC ye dǝro letǝnyi kui man kolzǝ kate kate zawalwa ndi ye rataltǝyin nǝm ngalaw natija dǝn wuwom kamtǝ ro.
RCGP RSC’s surveillance with PHE is defined as Health Protection under Regulation 3 of The Health Service (Control of Patient Information) Regulations 2002.
Sursuri kǝnga RCGP RSC’s ye dǝ rokko PHE ye dǝn dǝ sha nzǝrifo nǝlefa yen buwotin sidiya wuwom kǝn ǝ mi cida nǝlefa ye dǝn (bayan kam dondi ye yitkaw) Wuwom2002 ye.
This has been confirmed by PHE’s Caldicott Guardian’s Office.
Adǝ ye cidaram PHE ye PHE’s Caldicott Guardian’s ye dǝ ye tawatsǝna.
We do not see any increased risk to practices or practitioners taking part in this surveillance.
Ande ye tajirwafi ma tǝrana kǝla cida-a cidawu-a yen suro sursuri kǝngaye adǝ lan ruyende.
Infection prevention and control advice will follow extant national guidance.
Shawari kwasa faitǝ-a katǝ-a ye dǝ kashimo lardǝ ye kure ye dǝ zǝayin.
Any cases identified will be managed according to the PHE/NHS guidance in force at the time, including advice for identified contacts.
Kwasa asutǝna wo so futu kashimo PHE/NHS ye ro cistuwuyin shi dǝwo loktu dǝn cidatin ma dǝ, suro dǝn shawari am dǝwo Asutǝna ye-a son.
However, our training will include reminders about safe handling of specimens and revision of infection control measures anticipated to be high in our practices.
Adǝyeyi ma, darasǝ nde dǝ suro dǝn taktǝgǝ kǝla futu nzǝrifowa ro bu gotǝna dǝga rota-a tawtaw kǝnga-a kǝla katabwa kwasa tartǝgǝ kaltǝge ye-a tǝmatǝna cida nde dǝn nguwu ro waljin ro.
It is a key part of Regulation 12 about safe care and treatment, periodically inspected by the Care Quality Commission.
Shidǝ huwom 12 ye kǝla cistuwu nǝlefa ye-a kurun diwo-a yen, kǝla kǝlan cidaram nǝm ngalaw ro cistuwu ye Care ye dǝ ye kulashhin.
Travel History and Clinical Descriptors of the COVID-19 Infections
Bayan bǝlaro ye-a siffawa liyitariye-a tartǝgǝ COVID-19 ye
The RCGP RSC practices have been advised on the clinical coding that has been made available for COVID-19 across all CMR systems.
Cidawa RCGP RSC ye dǝ shawari tina kǝla fasal liyitariye dǝwo COVID-19 ye dǝro fasalla CMR ye dukso ro.
This includes information on coding of clinical descriptors (Table 4) and any recent travel history.
Adǝ ye suronzǝ dǝn bayan kǝla bayanna gǝrata liyitariye (Table 4)-a kuru bǝlaro la karǝngǝn tǝdǝnaye-a.
Establishment of Extended Virology Sampling
Kulashi kǝla kuli kwasaben kuratǝgǝna ma koktǝ
The RCGP RSC practices participating in the annual influenza virology surveillance have started sampling from patients showing symptoms of LRTI.
Cidawa RCGP RSC ye dǝwo kulashi kuli kwasabe kǝla tantayi yen saa saa lan tǝdin ma dǝro rǝbtana ma dǝ ye bu gotǝ badizana ba am dǝwo alamawa LRTI ye fǝlezana so yen.
This has led to initial early identification of background spread in low-risk patients.
Adǝ ye cidaamen tartǝgǝ kam dondi kambayi ye sǝkǝ daten Asutǝna.
As of March 7, 2020, the surveillance system has detected 2 cases of COVID-19 in low-risk patients with no history of travel through extended virological sampling.
Yim March 7, 2020 lan, Fasal sursuri kǝngaye dǝ ye kwasa COVID-19 ye 2 asuzǝ suro am dondi tajirwa ganayen sandi dǝwo tarihi bǝlarozana ye ba ma fasal kulashi kuli kwasabe ye shiro extended virological sampling gultin dǝ men.
This protocol describes how we have adapted a national influenza surveillance system to monitor community spread of an unexpected infection of COVID-19.
Kaida adǝ ye bayan cin kǝla futu Fasal lardǝye sursuri kǝnga kwasa tantayi ye dǝga gonye faidatena dǝn sawo kwasa COVID-19 ye tǝmatǝnyi lan suro jamaye ro tartǝgǝ dǝ kuru ro.
We have rapidly created and incorporated new codes to allow data recording, and are collecting data to monitor the effectiveness of containment strategies.
Ande ye nagaduro fasal bǝlin cituluye bayan gǝnatǝ ro, kuru sandi bayanna sansain kǝla katabwa kǝriwtǝbe dǝ kalkal ro cidajin wa ro kururo.
Through this surveillance, we intend to find out more about the epidemiology of COVID-19 in ambulatory care.
Sursuri kǝnga adǝ men, ilmu kǝla kwasa COVID-19 ye dǝn nguwu fando ro nyanyena suro am liyitarin rotǝnyi ro cistuwu yen.
In particular, its rate of spread, both temporal and geographical.
Musamman ma ro, futu tartǝgǝnzǝye, zahirnzǝ-a na dǝgana-a.
Our testing of low-risk patients will also inform whether the containment strategy that is based on virology testing of high-risk patients and their contacts plus self-isolation is effective.
Am dondi ganaye Rizabsǝnadeye fǝlejin kǝla katabwa kǝriwtǝbe dǝwo kǝla rizabi kuli kwasabe tǝdǝna kǝla am dondi zauro tajirwa yen ma dǝ-a am sandiro letana-an kunten dǝ ngǝlaro cidajin wa ro.
Containment should slow the spread, and there may be benefits in the management of spread from intense surveillance.
Kǝriwtǝdǝye tartǝgǝdǝ fulujin, kuru waneye tartǝgǝdǝro zauro sursuri kǝnga men cistuwu dǝn faida mbeji.
However, there may come a point at which the virus spreads more widely into the population, as has happened in Italy.
Adǝyeyi ma, loktu la waneye ishin ma mbeji sa kuli kwasabe dǝ zauro nguwu ro suro jama so yen tartǝgǝyin ma, futu Italy lan wazǝna dǝ yeyi.
Surveillance of low-risk patients should inform when we reach this tipping point and when infection rates start to remit.
Sursuri kǝnga am dondi dǝwo tajirwa ganaye dǝ ye fǝlejin sa nǝm zauro nguwu adǝ nayeya kuru sa adadu tartǝgǝ kwasa dǝ ye dǝ fulutiya.
The epidemiology of COVID-19 remains emergent.
Ilmu kǝla COVID-19 ye dǝ kwamison bǝlin ye tǝrayin na karaye.
The registration-based nature of UK primary care means that we will be able to create a complete picture of the cumulative incidence and duration.
Futu UK ye cistuwunzǝ badiyaram ye dǝ bab ro yuko yeyi dǝ ye mananzǝ dǝ ande ye rangnye kǝzǝbkǝ ro hawar jumla kwasa dǝ ye-a loktu gozǝna ye-a yiyen.
The surveillance system should be able to identify areas where COVID-19 spread is taking place that might be suitable for trials of antiviral therapy.
Fasal sursuri kǝngaye dǝ ye raksa naa dǝwo kwasa COVID-19 ye tartǝyin dǝwo waneye kurun kuli kwasabe jarabtǝ ro sandǝna wa ro asuzain.
We could also follow up on the effectiveness or any adverse reactions to these medicines or vaccinations.
Ande ye kuruman ngawo dǝ gaye ruyen kǝla Kurunwa adǝ-a kalimi-a dǝ ye nǝm ngǝlanza aw tiyiye watǝnza so dǝ ruyen.
Finally, early detection of a confirmed COVID-19 case has exemplified the rapid implementation of this enhanced surveillance in the national network.
Dare dajilamen, kwasa COVID-19 ye tawatkata dǝga asuta dǝ ye banazǝ nagaduro sursuri kǝnga dǝ suro fasal lardǝye dǝn cidatǝ sǝrana.
Safety of practices is our primary concern.
Nǝlefa cidaye dǝ shima mǝradǝ nde kǝn hawalmi ye wo.
The RCGP RSC has operated for over 50 years and has been involved in collecting samples to monitor disease and vaccine effectiveness through the Hong Kong flu pandemic of 1968/69, the Russian flu of 1977/78, and the 2009 Swine flu pandemic.
RCGP RSC dǝ saa 50 samin ro cidazǝna kuru bu gotǝ kwasa kulastǝ-a nǝm ngalaw kalimiye-a sǝdin kwasa tantayi ye bǝla Hong Kong ye saa 1968/69, kwasa tantayi ye bǝla Russia ye saa 1977/78, kuru tatanyi Swine ye saa 2009 ye dǝ-a.
We are not aware of any increased risk to practice staff or other patients from involvement in surveillance.
Hawar tajirwa la tǝrana ye kǝla cidawu aw am dondi la so yen sawu sursuri kǝnga dǝ sadǝna dino fanyiyende.
Pandemic preparedness is part of the role of the RCGP RSC.
Kwasa dina la ye ro dawartǝ dǝ suro cidawa RCGP RSC yen kara.
It is plausible that enhanced coding of information from contacts with the practices in RCGP RSC will reduce the likelihood of people who may be suspected COVID-19 cases being brought to the surgery inadvertently.
Bayanna gǝratǝ ngǝlaro tǝdǝna ma na am natǝna so yen cida RCGP RSC ye me dǝ am COVID-19 ye sǝtana ro tǝmatǝna so dǝga tiyata ro kudo ye muwontǝ nzǝ dǝ jire ro waljin.
Where cases are detected unexpectedly, it is probably helpful for that patient, their contacts, and the practice to know.
Na kwasasodǝ tǝmatǝnyi lan tuwandin, kam dondi adǝga, am letana, kuru cida dǝ-a banajin noza ro.
The impact on practices has been to close for a day, if a case is found, for deep cleaning and then reopen.
Futu cida dǝga lejin shima kawu fal ro zaktǝ, sa kwasa la tuwondiya, ngǝlaro gǝratǝ ro kuru daji waltǝ fǝrǝmtin.
The principal limitations of our system are the number of data points.
Awowa dǝwo ne fasal nde dǝro takkal sawudin ye gayanzǝ dǝ sandima adadu bayanna dǝ ye dǝ.
We are collecting serology and virology data from 100 sites, which covers a small group of the population.
Ande ye bu ngaltǝ-a bayanna kuli kwasabe-a gonyen naa 100 lan, Shi dǝwo ne am gana suro jama ye dǝ kǝrezǝna ma.
This has been satisfactory for monitoring influenza, but we are not certain if this is a sufficiently large sample for the COVID-19 outbreak.
Adǝ ye sursuri kǝnga tantayi ye kǝnasar tuwondǝna, amma tawadǝnda ba kǝla adǝma dǝ misal kǝzǝbkǝ ma falangtǝ COVID-19 ye wa ro.
Our sites (surveillance practices) are currently fixed, and it could be helpful to be able to rapidly onboard practices in regions where there are more cases.
Naa nde so dǝ (cidawa sursuri kǝnga ye) kǝrmaro tatama, kuru waneye faida ro waljin nagaduro cida baditǝ dǝ naa dǝwo kwasa dǝ nguwu so dǝn.
Currently, we will be reporting weekly.
Kǝrmaro dǝro, magǝ magǝn refot yiyen.
Our existing system can be enhanced to twice weekly, but maybe daily or hourly data should be our current approach.
Fasalnde kǝrmaye dǝ raktǝ tata maw lan ndi ro waljin, amma waneye bayanna yim yim ye aw awa awa ye shima kǝrmaro ganzanye ro waljin.
Opportunistic sampling for serology in children younger than 10 years might be limited due to the overall reduced rate of blood tests in children.
Bu gotǝ dǝwo duli sǝnana ye saa meu yin cidaan so ye dǝ gana ro waljin sawo adadu bu ngaltǝ duli ye dǝ fulutǝna ye dǝro.
The extended surveillance using the RCGP RSC-PHE network for the emergent COVID-19 outbreak has been established rapidly.
Sursuri kǝnga zawal RCGP RSC-PHE ye faidatǝ men, kǝla falangtǝ COVID-19 ye bǝlin ma dǝ yen nagaduro koktǝna.
The model of getting the appropriate informatics to enable capture of the required data has already been a success, with data recording starting the week the codes were created.
Fasal bayanna kǝzǝbtǝro fandoye banazǝ bayanna mǝradǝtǝna fandoye dǝn kǝnasar tuwondǝna, bayan ruwotǝ mawu bayan hǝratǝ dǝ baditǝna lan.
In addition, modifying the existing surveillance system to collect population data in a parallel way has also been effective.
Ngawo adǝyen, fasal sursuri kǝngaye kǝrmaye dǝga yasama Shi lan bayanna jamaye gotǝ dǝ ci tilowa men dǝ shi ye faidazǝna.
However, we are at present unsure as to whether the scale of this surveillance provides sufficient data to drive local containment strategies or if reporting infrequently meets the need of our information age.
Adǝyeyi ma, kǝrma dǝro ande dǝ tawadǝnde ba kǝla ngalno sursuri kǝngaye adǝ ye bayanna kǝzǝbkǝ ro cǝ katabwa suro fatoye men kǝriwtǝye suwudin wa ro aw la kǝla kǝlan refot yo ba dǝ ye mǝradǝnde bayan fantǝye zaman ye dǝga galjin wa ro.
Updating the diagnostic criteria of COVID-19 “suspected case” and “confirmed case” is necessary
Kaida kulashi kǝla COVID-19 ye dǝga bǝlintǝgǝ dǝ "kwasa tǝmatǝgǝna ma"-a "kwasa tawatkata ma"-a ye dǝ zauro faida
On 6 February 2020, our team had published a rapid advice guideline for diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infection, and this guideline provided our experience and make well reference for fighting against this pandemic worldwide.
Yim 6 February 2020, cidawu de ye kashimo shawari ye kulashi-a kurun diwo-a ye kǝla koronabairos bǝlin 2019 ye (2019-CoV) ye tartǝgǝ nzǝ ye dǝn lǝbsana, kuru kashimo adǝ ye ilmu nde-a nzukolto kǝla futu kwasa dinaye adǝga dina samman kǝriwtǝye cina.
However, the coronavirus disease 2019 (COVID-19) is a new disease, our awareness and knowledge are gradually increasing based on the ongoing research findings and clinical practice experience; hence, the strategies of diagnosis and treatment are also continually updated.
Adǝyeyi ma, kwasa koronabairos 2019 (COVID-19) ye dǝ kwasa dǝwo bǝlin, kǝla fatǝnde-a ilmunde-a dǝ gana ganan tǝrain lǝatar kulashi kǝrmaro tǝdin-a ilmu cida liyitariye-a men, adǝ nankaro, katabwa kulashi-a kurun diwo-a ye so dǝ ye sambiso ro fafaltin.
In this letter, we answered one comment on our guideline and provided the newest diagnostic criteria of “suspected case” and “confirmed case” according to the latest Diagnosis and Treatment Guidelines for COVID-19 (seventh version) that issued by the National Health Committee of the People’s Republic of China.
Suro watiya adǝyen, jawawu koro la kǝla kashimo ndeyen yiyena, kuru kaidawa bǝlin kǝla kulashi liyitariye kǝla "kwasa tǝmatǝgǝna"-a "kwasa tawatkata"-a ye dǝn yiyena lǝatar kulashi-a kurun diwo-a bǝlin yen kǝla COVID-19 ye dǝn COVID-19 (seventh version) shi dǝwo ne Komiti Nǝlefa lardǝye lardǝ China ye cina ma dǝ.
In December 2019, the 2019 novel coronavirus (2019-nCoV) has caused an outbreak, which is now officially named as the coronavirus disease 2019 (COVID-19) and the virus has been named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Suro December 2019 yen, kwasa coronavirusye bǝlin 2019 ye (2019-nCoV) dǝ yt sǝkǝ falangtǝ wazǝna, shi dǝwo ne kǝrmaro maila ro sha kwasa koronabairos ye 2019 (COVID-19) lan buwotin dǝ kuru kuli kwasabe dǝ sha kwasa yintǝye zauro zaw coronavirus 2 (SARS-CoV-2) lan buwotin.
On 11 March 2020, WHO characterized COVID-19 as a pandemic.
Yim 11 March 2020, WHO ye COVID-19 dǝga kwasa dinaye ro mawwono.
In order to fight against the SARS-CoV-2 infection, our team has developed a rapid advice guideline and that has been published online in Military Medical Research on 06 February 2020.
Tartǝgǝ SARS-CoV-2 ye dǝ fulutǝ ro, cidawu nde ye kashimo shawari ye nagaduye satandana kuru shi dǝwo ne onlayin lan lǝbsana suro kulashi kurun matǝye askǝrra ye dǝn yim 06 February 2020.
It has attracted a great attention since published.
Kawu lǝbtǝna wo so zauro hangal jamaye gǝrzǝna.
Note however that COVID-19 is a new disease, our awareness and knowledge is gradually increasing based on the ongoing research findings and clinical practice experience; hence, the strategies of diagnosis and treatment are also continually updated.
Adǝyeyi ma hangal gǝnatǝ, kǝla COVID-19 dǝ kwasa bǝlin yen, kǝla fatǝnde-a ilmunde-a dǝ gana ganan tǝrain lǝatar kulashi kǝrmaro tǝdin-a ilmu cida liyitariye-a, adǝ nankaro katabwa kulashi-a kurun diwo-a ye so dǝ sambiso ro bǝlintǝyin.
For instance the Diagnosis and Treatment Guidelines for COVID-19 issued by the National Health Committee of the People’s Republic of China (http://www.nhc.gov.cn/), among 16 January 2020 to 3 March 2020, has issued a total of seven editions with some contexts being substantively changed.
Misallo kashimo kulashi-a kurun diwo-a ye kǝla COVID-19 yen dǝwo Komiti Nǝlefa lardǝye lardǝ China ye sutuluwuna dǝ (http://www.nhc.gov.cn/), dawu 16 January 2020 lan sǝta 3 March 2020 ro suwudǝna ǝn, adadu jumla lǝbtǝ kashi tulur ye sutuluwuna kalmawa la faltǝna ro.
Now our guideline received a comment by Zhou et al., they introduced a simple scoring proposal based on their clinical experience.
Kǝrma dǝ kashimo ndǝ ye kǝla dǝn Zhou et al. So ye manazana, sandiye shawari bu gotǝna dǝ ye darajanzǝ asutaye saudǝ lǝatar ilmunza liyitaye ro.
Their work added new evidence for our guideline and also make valuable reference for this pandemic worldwide.
Cidanza dǝ ye kashimo nde dǝro hujja serana kuru nzukolto faida kǝla kwasa dinaye dǝro dina samma so ro sǝdǝna.
We endorse their significant work and express our thanks.
Ande ye chidanza taida dǝga ardinyena kuru askǝrande fǝlenyena.
However, their work also needs update according to the latest Diagnosis and Treatment Guidelines for COVID-19 (Trial seventh version) and recently studies.
Adǝyeyi ma, cidanza dǝ ye bǝlintǝgǝ mǝradǝzǝna futu kulashi bǝlin-a kurun diwo-a kǝla COVID-19 (Trial seventh version) dǝ ye fǝlezǝna dǝyeyi kuru nazaruwa bǝlin-a
According to the seventh edition (3 March 2020), to confirm the suspected case needs to combine any one item of epidemiological history features with two items of clinical manifestations to make a comprehensive analysis, or needs to meet three items of clinical manifestations if without clear epidemiological history:
Bakta kǝntulur (3 March 2020) ye fǝlezǝnadǝ yeyi, kwasa tǝmata dǝ tawattǝgǝ ro awowa ilmu kwasa tartǝgǝyin ye falnzǝ tuskatǝyin rokko dǝn awowa ndi sheda liyitaye-a bayan ilmu kwasa tartǝgǝyin ye dǝ baro walwono wa:
Epidemiological history: (1) a history of travel or residence in Wuhan city and surrounding areas, or other communities where COVID-19 cases had been reported in the last 14 days before symptom onset; (2) a history of contact with SARS-CoV-2 infectious cases (with positive nucleic acid test); (3) a history of contacting with patients with fever or respiratory symptoms from Wuhan city and surrounding areas, or other communities where COVID-19 had been reported in the last 14 days before symptom onset; (4) a history of contacting with cluster of confirmed cases (≥ 2 cases with fever and/or respiratory symptoms occurred within 2 weeks in small areas, such as home, office, class of school, etc).
Bayan Nzundu Kwasa Tartǝgǝyin ye : (1) bayan bǝrni Wuhan ye ro bǝlaro tǝna ye-a nabtǝna ye-a kuru bǝlamashi nzǝ-a ye, aw ngurowa gade COVID-19 fǝlangzǝna so-a suro kawu 14 kozǝna dǝ yen kawu alama kwasabe dǝ buro hawal yin badizana dǝn, (2) bayan kǝla kwasawa tartǝgǝyin ma SARS-CoV-2 ye ro letǝgǝye (with positive nucleic acid test); (ǝ) bayan kǝla kam kange aw kwasa yintǝye alama fǝlezǝna-a ro letǝgǝna bǝrni Wuhan-a mashinzǝ-a lan, aw ngurowa gade dǝwo kwasa COVID-19 ye falangzǝna suro kawu 14 yen tǝn kawu bǝro hawal alama dǝ badizana yen, (4) bayan kǝla am tawadǝro kwasa dǝ ye sǝtana ro letǝgǝnaye (≥ 2 kwasawa kange ya kǝllatǝ kuru/aw alama kwasa yintǝ ye suro mawu 2 yen fǝlezǝna ma gana lan, alam foto, cidaram, aji muwontiye, gade gabsǝna-a).
Clinical manifestations: (1) fever and/ or respiratory symptoms; (2) with imaging features of COVID-19 infection; (3) total white blood cell counts showing normal, decreased, or reduced lymphocyte count in the early onset stage.
Alamawa liyitari Turin: (1) kange-a/aw Alamawa yintǝye; (2) foto alamawa COVID-19 ye sǝtana ye; (ǝ) adadu jumla bu dǝwo shiro white blood cell gultin dǝ ye dǝ kalkal, fulutǝna, aw adadu or reduced lymphocyte ye dǝ loktu badiyaram dǝ man ganazǝna.
Diagnosing the confirmed case should base on suspected case with any one item of pathogenic or serological evidence as following: (1) real-time PCR test positive for SARS-CoV-2; (2) viral whole genome sequencing showing high homogeneity to the known novel coronaviruses; (3) positive for the specific IgM antibody and IgG antibody to SARS-CoV-2 in serum test; or a change of the SARS-CoV-2-specific IgG antibody from negative to positive, or titer rising ≥4 times in the recovery phase above that in the acute phase.
Kwasa tawatkata kulastǝ dǝ lǝatar kwasa tǝmata ye dǝwo awowa adǝ ye falnza sheda kwasa y-a aw ngaltǝ buye-a futu adǝ yeyi ro: (1) real-time PCR test dǝ SARS-CoV-2 mbeji ro fǝlezǝna; (2) viral whole genome sequencing dǝ zauro kwasa bǝlin koronabairos samǝn ro fǝlejin (ǝ) positive for the specific IgM antibody dǝ mbeji kuru IgG antibody to SARS-CoV-2 ye suro serum test yen mbeji; aw SARS-CoV-2-specific IgG antibody dǝ ye ba lan faltǝ mbeji ro waltǝ, aw titer dǝ habtin gade gade ≥4 ro suro kashi ngatǝ ye dǝn kashi zauro zawye dǝga kozǝna ro.
We can see that the real-time PCR test for nucleic acid in respiratory tract or blood samples was added to the second (18 January 2020) and third (22 January 2020) editions.
Rangnye ruyen futu real-time PCR test nucleic acid ye dǝ suro yintǝram aw bu gotǝna dǝ ye dǝ lǝbtǝ kǝn ndimi ye dǝro tǝrana (18 January 2020)-a kǝn yakkǝmi (22 January 2020) -a so ro.
The pathogenic detection of blood sample was added to the fourth (27 January 2020) and fifth (8 February 2020) editions; and then the serological evidence was added to the seventh edition.
Bu gotǝmen kwasa asuta dǝ lǝbtǝ kǝn diyewmi dǝro tǝrana (27 January 2020)-a kǝn uwumi (8 February 2020)-a; kuru daji Hujjawa bu ngaltǝ ye dǝ lǝbtǝ kǝn tulurmi dǝ ro tǝra.